In one paragraphArticle in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Mikel García-PugaCellular Oncology Group, Biogipuzkoa Health Research Institute, Paseo Dr. Beguiristain s/n, 20014 San Sebastian, Spain.ORCID 0000-0002-2975-934X Gorka GerenuNeuroscience Area, Biogipuzkoa Health Research Institute, Biodonostia Institute, 20014 San Sebastian, Spain.ORCID 0000-0002-4981-5791 Ariadna BargielaTranslational Genomics Group, University Institute for Biotechnology and Biomedicine (BIOTECMED), University of Valencia, 46100 Burjasot, Spain.ORCID 0000-0003-4336-2522 Jorge Espinosa-EspinosaTranslational Genomics Group, University Institute for Biotechnology and Biomedicine (BIOTECMED), University of Valencia, 46100 Burjasot, Spain.ORCID 0000-0003-0098-5201 Laura Mosqueira-MartínNeuroscience Area, Biogipuzkoa Health Research Institute, Biodonostia Institute, 20014 San Sebastian, Spain.ORCID 0000-0002-5714-7682 Maialen Sagartzazu-AizpuruaJoxe Mari Korta R&D Center, Department of Organic Chemistry I, University of the Basque Country, 20014 San Sebastian, Spain.
Jesús M AizpuruaJoxe Mari Korta R&D Center, Department of Organic Chemistry I, University of the Basque Country, 20014 San Sebastian, Spain.ORCID 0000-0002-1053-5776 Ainara Vallejo-IllarramendiNeuroscience Area, Biogipuzkoa Health Research Institute, Biodonostia Institute, 20014 San Sebastian, Spain.ORCID 0000-0002-2409-8263 Rubén ArteroTranslational Genomics Group, University Institute for Biotechnology and Biomedicine (BIOTECMED), University of Valencia, 46100 Burjasot, Spain.ORCID 0000-0003-1596-047X Adolfo López de MunainNeuroscience Area, Biogipuzkoa Health Research Institute, Biodonostia Institute, 20014 San Sebastian, Spain.ORCID 0000-0002-9509-4032 Ander MatheuCellular Oncology Group, Biogipuzkoa Health Research Institute, Paseo Dr. Beguiristain s/n, 20014 San Sebastian, Spain.
Funding
Carlos III Institute PI22/01905
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Aging, PrematureFibroblastsMyotonic DystrophyPhenotypeTacrolimus Binding Protein 1AAnimalsCalciumCell ProliferationCell SurvivalDisease Models, AnimalHumansLigandsMaleOxidative StressCalciumLigandsTacrolimus Binding Protein 1Aextended longevityFKBP12/RyR interactionmultisystem recoverymyotonic dystrophyoxidative stress
Identifiers
PMID39682688
PMCPMC11639790
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390